Endocrine Abstracts

Pegvisomant (PEG) is effective in acromegaly control and exerts a positive impact on glucose metabolism. The current study aimed at investigating the effects of 10-years PEG treatment on disease control, pituitary adenoma size, and metabolic profile in patients with acromegaly resistant to somatostatin analogues (SRLs). Twenty-two patients (9 men,13 women, age 45.54 ± 12.83 years) treated with PEG for 10 years, in monotherapy or in combination with SRLs, were included in ...

Pasireotide is a second-line therapy for acromegaly, that allows to obtain disease control in patients previously uncontrolled. However, pasireotide-induced hyperglycemia is of major concern. Currently, few data concerning prolonged use of pasireotide are available. The current retrospective study aimed at investigating the efficacy and safety of long-term pasireotide therapy. Sixteen consecutive patients (5 males, 11 females, age 47 ± 11 years) undergoing pasireotide for...

Colon polyps represent a frequent complication of acromegaly. Knowledge about prevalence and risk factors of polyps’ recurrence in acromegalic patients is still limited. The current retrospective study aimed at investigating polyps’ prevalence and recurrence risk factors in acromegalic patients. One hundred and forty-three patients (73 males, 70 females) referring to “Federico II” university diagnosed with acromegaly from 2000 to 2022 who underwent at least...

Purpose: The present study aims to investigate the effects of hyperprolactinemia (HPRL) and its pharmacological control with Cabergoline (CAB) on the risk of fractures in male patients affected by prolactinoma.Methods: Observational single-center study was conducted on 39 male patients (median age 49±12,4 y) with prolactinoma, including 37 with macroprolactinoma and 2 with empty sellae. In patients PRL levels at diagnosis (PRL 0’), PRL at evalu...

Purpose: Dopaminergic system is implicated in the development of sleep disorders, and dopaminergic agents are used in clinical practice to treat daytime sleepiness and sleep disorders. The present study aimed at investigating the effects of hyperprolactinemia and its control with dopamine-agonists (DA) on sleep quality, excessive daytime sleepiness (ESS) and risk of obstructive sleep apnea syndrome (OSAS) in prolactinomas.Methods: A single-centre study w...

Sleep apnea (SA) is a common acromegaly comorbidity, influencing patients’ quality of life and mortality risk. Despite its importance, SA frequently remains undiagnosed, and its real prevalence seems to be underestimated. The current observational study aimed at investigating the role of Berlin questionnaire (BQ) and Epworth sleepiness scale (ESS) in assessing the risk of SA in this high-risk population, and to compare the results with an age-and gender-matched health coh...

Introduction: Cardiac abnormalities are common in patients with acromegaly and contribute to the increased morbidity and mortality of the disease. Cardiac magnetic resonance (CMR) is the established, non-invasive gold standard for measuring morpho-functional changes of the heart. We aimed to detect cardiac alterations in patients with acromegaly through CMR and to identify potential risk factors associated with cardiac impairment.Materials and methods: T...

Rationale: Type 2 diabetes mellitus (DM) is common in patients with Cushing’s disease (CD) and Acromegaly (AC), and contributes to increased mortality. This study aimed at investigating the prevalence and characteristics of DM in CD and AC patients at diagnosis and after disease control (DC).Patients and Methods: 34 CD patients (8M,26F, 24 microadenomas(mA),6 macroadenomas (MMA) and 4 empty sella) and 35 AC patients (16M,19F, 7 mA,28 MMA) were inclu...

Despite the myocardial prolactin (PRL) binding activity and the known effect to enhance contractility in the isolated rat heart, little information is available concerning the cardiovascular consequences of hyperprolactinemia in humans. To elucidate the effects of chronic hyperprolactinemia on cardiac structure and function, twenty-four patients with isolated PRL-secreting adenoma and twenty-four controls underwent a complete mono- and two-dimensional Doppler echocardiography....

Pasireotide (PAS) has a safety profile similar to first-generationsomatostatin analogues (SSA), except for a higher frequency of hyperglycaemia-related adverse events (AEs). However, consensus on the best management of PAS-induced hyperglycaemia in acromegalic patients has still to be defined. The current study aims at investigating the effects of long-term PAS treatment on glucose metabolism, by evaluating the clinical management of hyperglycemia-relatedAEs in acromegalic pat...